Donald R. Lazarus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donald R. Lazarus has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- David E. Ost
Department of Pulmonary Medicine, MD Anderson Cancer Center, The University of Texas, Houston, USA
4 shared publications - Babith J. Mankidy
Department of Pulmonary and Critical Medicine, Baylor College of Medicine, Houston, TX, USA
2 shared publications Carlos A. Jimenez
Department of Pulmonary Medicine, and
2 shared publicationsGeorge A. Eapen
Department of Pulmonary Medicine, Department of Biostatistics, Section of Health Services Research, The University of Texas MD Anderson Cancer Center
2 shared publicationsRoberto F. Casal
Division of Pulmonary and Critical Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
2 shared publications- Roberto F. Casal
The University of Texas M.D. Anderson Cancer Center
2 shared publications
Latest Publications
- 7 August 2023
- Published by Springer Nature in Current Pulmonology Reports
- Vol. 12 (4) , 210-217
Pleuroscopy: Update on Indications, Techniques, and Limitations
- 7 August 2023
- Published by Springer Nature in Current Pulmonology Reports
- Vol. 12 (4) , 210-217
Pleuroscopy: Update on Indications, Techniques, and Limitations
- Open Access
- 1 July 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (7) , 3501-3504
Extending the indications for indwelling pleural catheters: a tube for all seasons
Extending the indications for indwelling pleural catheters: a tube for all seasons
- 1 July 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (7) , 3501-3504
Open AccessExtending the indications for indwelling pleural catheters: a tube for all seasons
Extending the indications for indwelling pleural catheters: a tube for all seasons
- 15 May 2023
- Published by Elsevier in Respiratory Medicine
- Vol. 214, 107277
High risk lung nodule: A multidisciplinary approach to diagnosis and management
- 15 May 2023
- Published by Elsevier in Respiratory Medicine
- Vol. 214, 107277
High risk lung nodule: A multidisciplinary approach to diagnosis and management
- 1 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 28 (4) , 288-293
Therapeutic bronchoscopy for malignant central airway obstruction: impact on quality of life and risk-benefit analysis
Purpose of review: Malignant central airway obstruction (CAO) is a common complication in cancer and confers significant symptom burden and reduction in quality of life. Multiple bronchoscopic interventions exist for malignant CAO. In this review, we discuss the role of therapeutic bronchoscopy in the management of malignant CAO, emphasizing its impact on symptom control and quality of life while balancing the risks and benefits of intervention. Recent findings: Significant practice variations exist among practitioners of therapeutic bronchoscopy, and limited data exist to guide real-time clinical decision-making. Recent analyses demonstrate that therapeutic bronchoscopy is effective for symptoms associated with malignant CAO with infrequent complications. These studies also show that many of the improvements in symptoms and quality of life are sustained after intervention and are associated with improved overall survival in patients with malignant CAO. Recent data have also shown that the improvement in symptoms associated with therapeutic bronchoscopy may enable more definitive cancer treatment, further improving patient outcomes. Summary: Therapeutic bronchoscopy is safe and effective at improving patient-centered outcomes in malignant CAO. Research is ongoing to better understand its optimal role in this setting, refine decision-making regarding advanced bronchoscopic interventions, and further improve patient outcomes.
- 1 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 28 (4) , 288-293
Therapeutic bronchoscopy for malignant central airway obstruction: impact on quality of life and risk-benefit analysis
Purpose of review: Malignant central airway obstruction (CAO) is a common complication in cancer and confers significant symptom burden and reduction in quality of life. Multiple bronchoscopic interventions exist for malignant CAO. In this review, we discuss the role of therapeutic bronchoscopy in the management of malignant CAO, emphasizing its impact on symptom control and quality of life while balancing the risks and benefits of intervention. Recent findings: Significant practice variations exist among practitioners of therapeutic bronchoscopy, and limited data exist to guide real-time clinical decision-making. Recent analyses demonstrate that therapeutic bronchoscopy is effective for symptoms associated with malignant CAO with infrequent complications. These studies also show that many of the improvements in symptoms and quality of life are sustained after intervention and are associated with improved overall survival in patients with malignant CAO. Recent data have also shown that the improvement in symptoms associated with therapeutic bronchoscopy may enable more definitive cancer treatment, further improving patient outcomes. Summary: Therapeutic bronchoscopy is safe and effective at improving patient-centered outcomes in malignant CAO. Research is ongoing to better understand its optimal role in this setting, refine decision-making regarding advanced bronchoscopic interventions, and further improve patient outcomes.
- 9 March 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 196, 106802
Update on the diagnosis and management of malignant pleural effusions
- 9 March 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 196, 106802
Update on the diagnosis and management of malignant pleural effusions
- 1 August 2018
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 35, 93-96
Bronchoscopic resection of a tracheobronchial leiomyoma in a pregnant patient
- 1 August 2018
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 35, 93-96
Bronchoscopic resection of a tracheobronchial leiomyoma in a pregnant patient
- 31 May 2018
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (6) , 645-657
IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer
Somatic mutations can promote malignant transformation of airway epithelial cells and induce inflammatory responses directed against resultant tumors. Tumor-infiltrating T lymphocytes (TIL) in early-stage non–small cell lung cancer (NSCLC) secrete distinct proinflammatory cytokines, but the contribution of these TILs to tumor development and metastasis remains unknown. We show here that TILs in early-stage NSCLC are biased toward IL17A expression (Th17) when compared with adjacent tumor-free tissue, whereas Th17 cells are decreased in tumor infiltrating locoregional lymph nodes in advanced NSCLC. Mice in which Pten and Smad4 (Pts4d/d) are deleted from airway epithelial cells develop spontaneous tumors, that share genetic signatures with squamous- (SQ.2b), and adeno- (AD.1) subtypes of human NSCLC. Pts4d/d mice globally lacking in IL17a (Pts4d/dIl17a–/–) showed decreased tumor latency and increased metastasis. Th17 cells were required for recruitment of CD103+ dendritic cells, and adoptive transfer of IL17a-sufficient CD4+ T cells reversed early tumor development and metastasis in Pts4d/dIl17a–/– mice. Together, these findings support a key role for Th17 cells in TILs associated with the Pts4d/d model of NSCLC and suggest therapeutic and biomarker strategies for human SQ2b and AD1 lung cancer. Cancer Immunol Res; 6(6); 645–57. ©2018 AACR.
- 31 May 2018
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (6) , 645-657
IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer
Somatic mutations can promote malignant transformation of airway epithelial cells and induce inflammatory responses directed against resultant tumors. Tumor-infiltrating T lymphocytes (TIL) in early-stage non–small cell lung cancer (NSCLC) secrete distinct proinflammatory cytokines, but the contribution of these TILs to tumor development and metastasis remains unknown. We show here that TILs in early-stage NSCLC are biased toward IL17A expression (Th17) when compared with adjacent tumor-free tissue, whereas Th17 cells are decreased in tumor infiltrating locoregional lymph nodes in advanced NSCLC. Mice in which Pten and Smad4 (Pts4d/d) are deleted from airway epithelial cells develop spontaneous tumors, that share genetic signatures with squamous- (SQ.2b), and adeno- (AD.1) subtypes of human NSCLC. Pts4d/d mice globally lacking in IL17a (Pts4d/dIl17a–/–) showed decreased tumor latency and increased metastasis. Th17 cells were required for recruitment of CD103+ dendritic cells, and adoptive transfer of IL17a-sufficient CD4+ T cells reversed early tumor development and metastasis in Pts4d/dIl17a–/– mice. Together, these findings support a key role for Th17 cells in TILs associated with the Pts4d/d model of NSCLC and suggest therapeutic and biomarker strategies for human SQ2b and AD1 lung cancer. Cancer Immunol Res; 6(6); 645–57. ©2018 AACR.
- 1 September 2017
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 196 (5) , e12-e13
Obstructive Post-tracheotomy Granulation Tissue
- 1 September 2017
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 196 (5) , e12-e13
Obstructive Post-tracheotomy Granulation Tissue
- 21 June 2016
- Published by American Medical Association (AMA) in JAMA
- Vol. 315 (23) , 2621
Lung Volume Reduction Coils for Severe Emphysema
To the Editor The REVOLENS trial1 found that bronchoscopic treatment with nitinol coils vs usual care improved exercise capacity in patients with severe emphysema and adds to the growing literature on endobronchial treatment of emphysema.2,3
- 21 June 2016
- Published by American Medical Association (AMA) in JAMA
- Vol. 315 (23) , 2621
Lung Volume Reduction Coils for Severe Emphysema
To the Editor The REVOLENS trial1 found that bronchoscopic treatment with nitinol coils vs usual care improved exercise capacity in patients with severe emphysema and adds to the growing literature on endobronchial treatment of emphysema.2,3